Narrative Review of the Pharmacodynamics, Pharmacokinetics, and Toxicities of Illicit Synthetic Cannabinoid Receptor Agonists.

IF 3.3 3区医学 Q2 CHEMISTRY, MEDICINAL Mini reviews in medicinal chemistry Pub Date : 2024-01-01 DOI:10.2174/1389557523666230515163107

Matilda Lea Houston, Jody Morgan, Celine Kelso

{"title":"Narrative Review of the Pharmacodynamics, Pharmacokinetics, and Toxicities of Illicit Synthetic Cannabinoid Receptor Agonists.","authors":"Matilda Lea Houston, Jody Morgan, Celine Kelso","doi":"10.2174/1389557523666230515163107","DOIUrl":null,"url":null,"abstract":"Background: Synthetic cannabinoid receptor agonists (SCRAs) are the most diverse class of new psychoactive substances worldwide, with approximately 300 unique SCRAs identified to date. While the use of this class of drug is not particularly prevalent, SCRAs are associated with several deaths every year due to their severe toxicity.Methods: A thorough examination of the literature identified 15 new SCRAs with a significant clinical impact between 2015 and 2021.Results: These 15 SCRAs have been implicated in 154 hospitalizations and 209 deaths across the US, Europe, Asia, and Australasia during this time period.Conclusion: This narrative review provides pharmacodynamic, pharmacokinetic, and toxicologic data for SCRAs as a drug class, including an in-depth review of known pharmacological properties of 15 recently identified and emerging SCRAs for the benefit of researchers, policy makers, and clinicians who wish to be informed of developments in this field.","PeriodicalId":18548,"journal":{"name":"Mini reviews in medicinal chemistry","volume":" ","pages":"92-109"},"PeriodicalIF":3.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mini reviews in medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1389557523666230515163107","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Synthetic cannabinoid receptor agonists (SCRAs) are the most diverse class of new psychoactive substances worldwide, with approximately 300 unique SCRAs identified to date. While the use of this class of drug is not particularly prevalent, SCRAs are associated with several deaths every year due to their severe toxicity.

Methods: A thorough examination of the literature identified 15 new SCRAs with a significant clinical impact between 2015 and 2021.

Results: These 15 SCRAs have been implicated in 154 hospitalizations and 209 deaths across the US, Europe, Asia, and Australasia during this time period.

Conclusion: This narrative review provides pharmacodynamic, pharmacokinetic, and toxicologic data for SCRAs as a drug class, including an in-depth review of known pharmacological properties of 15 recently identified and emerging SCRAs for the benefit of researchers, policy makers, and clinicians who wish to be informed of developments in this field.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

关于非法合成大麻素受体激动剂的药效学、药代动力学和毒性的叙述性综述。

背景：合成大麻素受体激动剂（SCRAs）是世界上种类最多的一类新型精神活性物质，迄今已发现约 300 种独特的 SCRAs。虽然这类药物的使用并不特别普遍，但由于其严重的毒性，合成大麻素受体激动剂每年都会导致数人死亡：方法：通过对文献的深入研究，确定了 2015 年至 2021 年间 15 种具有重大临床影响的新 SCRAs：结果：在此期间，美国、欧洲、亚洲和大洋洲有154例住院和209例死亡与这15种SCRA有关：这篇叙述性综述提供了作为一类药物的 SCRAs 的药效学、药代动力学和毒理学数据，包括对 15 种最近发现的和新出现的 SCRAs 的已知药理特性的深入综述，供希望了解该领域发展动态的研究人员、政策制定者和临床医生参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Mini reviews in medicinal chemistry 医学-医药化学

CiteScore

7.80

自引率

0.00%

发文量

231

审稿时长

6 months

期刊介绍： The aim of Mini-Reviews in Medicinal Chemistry is to publish short reviews on the important recent developments in medicinal chemistry and allied disciplines. Mini-Reviews in Medicinal Chemistry covers all areas of medicinal chemistry including developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, drug targets, and natural product research and structure-activity relationship studies. Mini-Reviews in Medicinal Chemistry is an essential journal for every medicinal and pharmaceutical chemist who wishes to be kept informed and up-to-date with the latest and most important developments.